Matches in Wikidata for { <http://www.wikidata.org/entity/Q74274191> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- Q74274191 description "assaig clínic" @default.
- Q74274191 description "clinical trial" @default.
- Q74274191 description "clinical trial" @default.
- Q74274191 description "clinical trial" @default.
- Q74274191 description "clinical trial" @default.
- Q74274191 description "ensaio clínico" @default.
- Q74274191 description "ensayo clínico" @default.
- Q74274191 description "ensayu clínicu" @default.
- Q74274191 description "essai clinique" @default.
- Q74274191 description "klinisch onderzoek" @default.
- Q74274191 description "клінічне випробування" @default.
- Q74274191 name "Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC" @default.
- Q74274191 name "Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC" @default.
- Q74274191 type Item @default.
- Q74274191 label "Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC" @default.
- Q74274191 label "Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC" @default.
- Q74274191 prefLabel "Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC" @default.
- Q74274191 prefLabel "Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC" @default.
- Q74274191 P1132 Q74274191-C6C66896-BEED-4FA4-9C24-21063D565E85 @default.
- Q74274191 P1476 Q74274191-E37250A6-BD76-4A80-8FCC-843E7B298967 @default.
- Q74274191 P1813 Q74274191-BA435181-B886-44F3-AFCB-993E6CEA3FEC @default.
- Q74274191 P2899 Q74274191-FAD5A98F-0453-4D27-B71B-FE0465E98733 @default.
- Q74274191 P3098 Q74274191-A8D12CD4-C0DC-41C8-838C-F012CD823466 @default.
- Q74274191 P31 Q74274191-75808C82-474A-4699-A8B7-123A3D1D5847 @default.
- Q74274191 P4135 Q74274191-2242E4B2-42CF-4C54-A926-C9E7E6CB8D37 @default.
- Q74274191 P4844 Q74274191-5AF4AB13-4FD7-47A8-A45D-A5FFBFF46825 @default.
- Q74274191 P4844 Q74274191-EFCDC559-C6B2-4D39-8609-A5EF02F70CD3 @default.
- Q74274191 P4844 Q74274191-F710BF4D-92C3-42F8-B6CC-D171233D830C @default.
- Q74274191 P580 Q74274191-0A055B99-B15D-488C-BE96-45648F68CA77 @default.
- Q74274191 P582 Q74274191-8BE7AA56-8E9D-49C0-A448-D598F5AD9A90 @default.
- Q74274191 P6099 Q74274191-EEBA3611-D371-4009-B601-55B33A557954 @default.
- Q74274191 P8363 Q74274191-E497286E-77F5-431D-997E-0471FE37F201 @default.
- Q74274191 P859 Q74274191-A7516740-4EAC-4CAB-B720-1B6A3BEEC207 @default.
- Q74274191 P1132 "+105" @default.
- Q74274191 P1476 "A Multicenter, Randomized, Phase II Study of Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Advanced or Locally-advanced Osimertinib-resistant Non-squamous Non-small Cell Lung Cancer (ALTER-L031)" @default.
- Q74274191 P1813 "PCA" @default.
- Q74274191 P2899 "+18" @default.
- Q74274191 P3098 "NCT04136535" @default.
- Q74274191 P31 Q30612 @default.
- Q74274191 P4135 "+75" @default.
- Q74274191 P4844 Q21506464 @default.
- Q74274191 P4844 Q415220 @default.
- Q74274191 P4844 Q415588 @default.
- Q74274191 P580 "2019-10-18T00:00:00Z" @default.
- Q74274191 P582 "2021-12-31T00:00:00Z" @default.
- Q74274191 P6099 Q42824440 @default.
- Q74274191 P8363 Q78089383 @default.
- Q74274191 P859 Q495015 @default.